This year has seen more than its share of wildly successful investments, largely playing off of the pandemic — led by biotechnology stocks trying to treat, fight or prevent COVID-19 infections, and the (mostly technology) stocks that rode the accelerating adoption of remote work and play in the wake of “stay at home” and “social […]
Articles
The term “the duration” immediately recalls the Second World War. Nobody had any idea when it would be over, and so discussions of a lot of World War II-related events and conditions prominently featured the phrase “for the duration” – as in great numbers of combat fatalities would continue to be reported for the duration, […]
This article was originally posted on August 27, when we first saw these ads circulating… apparently lots of folks missed it, and the ads are running hot and heavy again, so we’re re-posting it here to help answer a flood of new reader questions. The stock teased has popped 40-50% or so on the Stansberry […]
Newsletters have taken to hiring spokespeople for their promo videos, trying to give them that extra flash of veritas and professionalism and a nice “anchor voice”, and this time it’s actress and former journalist Suzanne Sena that Money Morning brings in to pitch their “super vaccine” idea… which doesn’t mean anything about the stock, of […]
This will surely not be the last time Doc Gumshoe turns his attention to the pandemic that is now imposing misery on many parts of the world. I need to acknowledge that when what was then generally called the Wuhan virus first came to my attention, I expressed the view that, despite the dire […]
This article was originally published on May 28, 2020, when we first saw these ads — they have recently been re-circulating as the June 30 date approaches and vaccine interest rises again. What follows has not been updated since May 28, though I did add an updated note at the bottom. We haven’t covered a […]
I’ve gotten a few questions about the latest Technology Profits Confidential (currently $79/yr) tease from Ray Blanco, so although it’s a few weeks old now, and started circulating right in the heat of the first coronavirus downturn in mid-March, I thought I’d take a look today. It is still a current ad, I got it […]
Ian Wyatt has been out over the past couple weeks with some “webinars” in which he talks up the coronavirus outbreak (for an hour!) and then ends his show with a tease about several “special reports” on the stocks he thinks will make you a lot of money as we fight COVID-19… and, of course, […]
Having just devoted an entire Doc Gumshoe piece to the notorious coronavirus (COVID 19), I’m going to make those coronavirus updates brief – it looks to me as though the news media is devoting a major part of its capacity to covering most aspects of this pandemic – and, yes, it now certainly looks like […]
That headline is not in my words, of course (that’s why I use those handy little quotation marks), but it’s the headline from the latest Nick Hodge ad that’s been getting a lot of attention from Gumshoe readers. Hodge is pitching this new device, which apparently faces a big moment on June 30, as a […]
Stansberry Venture is a high-end ($5,000/yr) newsletter that focuses on small “breakthrough” type companies, so far mostly in biotech and technology as far as I’ve seen. It’s the heir, roughly speaking, of Stansberry’s old Phase 1 newsletter that used to often pitch biotech, tech and junior mining stocks. It’s helmed by Dave Lashmet, who was […]
The latest screed from Danielle O’Dell for the Money Map Report is aimed at first getting you all fired up about Obamacare, in case you’re one of the seven people in the United States that doesn’t already have a strong opinion about that law’s impending enactment, and then, more importantly, at telling you that she’s […]
Patrick Cox has found a new home — he has issued many a tempting teaser campaign over the years, and I was wondering what had happened to him after leaving his Breakthrough Technology Alert in the hands of Ray Blanco this Summer. Well, I can stop wondering — he jumped to a new publisher and […]
And we’re back! Today, it’s a biotech teaser from Brian Hicks for Steve Christ’s The Wealth Advisory (we last looked at one of his a few months back, when he was predicting a big move in Geron by this Spring — that one’s still on the clock, so we’ll see). This time the tease is […]
We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.
More Info
Comments
Based on the price and the below article, the company may be INO or DNA. Luke Lango isn't part of this specific article...
I subscribed to Lashmet's letter three years ago. While I did not take all of his suggestions, I did invest in BIIB, IN...
How about the blatant, unabashed, pump-and-dump of select vaccine stocks? Does that qualify for the (Pandemic) Turkey of...
Made a bundle with INO , MRNA not quit as much with BNTX...
I'm just listening to Robinson's shpiel right now and cracking up because I've been in INO since March and VXRT for week...
I did watch Robinson's presentation on Covid-19 stocks and was intrigued by it. I starting researching to find the sto...
Did you mean INO?...
I have been a paid member here for years and have invested in many vaccine stocks. I like this one the best for COVID-1...
My problem with INO and I own both it and SRNE is that they have never successfully brought any of their vaccines to ma...
COVID Teaser, NVAX shot up from $7 to $50, Buy the rumor sell the news is probably as good as it gets for these compani...
I thtoght Moderna would be the winner of this race to profit! Another one is Abivxax with their ABX 464 Covidv pill tha...
Why would corrupt class action lawyers and vulture shortsellers be attacking INO? Time for SEC to limit or ban shortsell...
I hold INO and GILD. GILD is the less risky in my view. What’s yours?...
Ray has pushed INO and GILD multiple times over the prior month but no mention of REGN in this publication....
Thanks Travis! Blanco might back off Inovio (INO) now, as a Class Action was just filed against Inovio, per this articl...
I bot INO years ago on the possibility of a vaccine for ebola. Rode it down under $2 and was glad for the chance to ge...
INO very likely to give a wild and woolly ride. Stock has the potential to run hard and fast - probably only on a sho...
INO in fraud investigation for false Covid19 vaccine claims? Class action from investors in progress.......
So INO (MY LOSER) IS A WILD CARD, LOL, HAHA, ROTFL, I JUST THOUGHT IT WAS A DEAD CAT, WITHNO BOUNCE!...
By pure coincidence, I have purchased 3 stocks related to the virus and they happen to be the three we are discussing he...
INO has crashed and burned with announcement of huge investor lawsuit....
INO seem to jump on every outbreak with a we are just about there proclamation.... they did it with SARS and MERS with n...
Yes. I have been investing on INO, TRIL, and Codx. Nice gains to offset the other losses....
10 days back I purchased INO, ( Inovio Pharma) and it is now over 200% up in so many days. Anyone has any experience ...
Speaking of virus plays- on Tuesday I got a buy trigger on INO at 5.05. I bought 1000 shares and went on with my day. ...
Doc - A better way to gauge the real death rate might be to look at cases where the infection has run its course, and se...
I applaud your closely researched documentation and would also like to hear about, and you may be able to provide a foll...
$ONCS reduced to skeletal 20180124 - When the geauxing gets tough, the tough get geauxing.... $ARTH ow, $INO sp - I...